Clown-Free Zone... sorry, no clowns allowed Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Earlie who wrote (260451)	9/16/2003 10:04:04 AM
From: ild	Read Replies (2) of 436258

09:38 ET Vasogen started with a Buy at Needham; tgt $9 (VSV) 5.05 +0.20: Needham is initiating coverage of Vasogen with a Buy rating and a 12-month target price of $9. It's a biopharmaceutical co focused on immune modulation therapy for the treatment of cardiovascular and other inflammatory diseases. Its lead product, IMT, is in Phase 3 trials for two large market areas: congestive heart failure and peripheral arterial disease. Firm expects IMT to be on the market in 1Q06. Firm believes stock is a very good investment opportunity in the cardiovascular space, given it has a late-stage product with novel mechanism of action, convincing early trial results, and a strong management and science team.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next